Performance of the WID-qEC test versus sonography to detect uterine cancers in women with abnormal uterine bleeding (EPI-SURE): a prospective, consecutive observational cohort study in the UK

Evans, Iona; Reisel, Daniel; Jones, Allison; Bajrami, Alba; Nijjar, Simrit; Solangon, Sarah Annie; Arora, Rupali; Redl, Elisa; Schreiberhuber, Lena; Ishaq-Parveen, Isma; Rothärmel, Julia; Herzog, Chiara; Jurkovic, Davor; Widschwendter, Martin

doi:10.1016/s1470-2045(23)00466-7

Cited by 5 publications

(6 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Alternatively, vaginal tampons can be used to collect cervicovaginal fluid, representing an inexpensive, easy-to-use self-collection system that is more likely to appeal to women. The samples can be analysed by next-generation sequencing to identify somatic mutations [ 56 ] or, of notable promise, undergo methylation testing [ 57 ]. The WID-qEC test, a three-marker test that appraises DNA methylation in the gene regions of GYPC and ZSCAN12 has been shown to outperform the transvaginal ultrasound measurement of endometrial thickness in the diagnosis of endometrial cancer (AUC WID-qEC 0.94 vs.…”

Section: Advances In Early Diagnosismentioning

confidence: 99%

“…The WID-qEC test, a three-marker test that appraises DNA methylation in the gene regions of GYPC and ZSCAN12 has been shown to outperform the transvaginal ultrasound measurement of endometrial thickness in the diagnosis of endometrial cancer (AUC WID-qEC 0.94 vs. ET measurement 0.87) among women with abnormal uterine bleeding [ 57 ]. The high negative predictive value of the test means that it could be used to reduce the number of women requiring invasive histological assessments.…”

Section: Advances In Early Diagnosismentioning

confidence: 99%

See 1 more Smart Citation

Recent Advances in Endometrial Cancer Prevention, Early Diagnosis and Treatment

Baker-Rand,

Kitson

2024

Cancers

View full text Add to dashboard Cite

Endometrial cancer is the sixth commonest cancer in women worldwide, with over 417,000 diagnoses in 2020. The disease incidence has increased by 132% over the last 30 years and is set to continue to rise in response to an ageing population and increasing global rates of obesity and diabetes. A greater understanding of the mechanisms driving endometrial carcinogenesis has led to the identification of potential strategies for primary disease prevention, although prospective evaluation of their efficacy within clinical trials is still awaited. The early diagnosis of endometrial cancer is associated with improved survival, but has historically relied on invasive endometrial sampling. New, minimally invasive tests using protein and DNA biomarkers and cytology have the potential to transform diagnostic pathways and to allow for the surveillance of high-risk populations. The molecular classification of endometrial cancers has been shown to not only have a prognostic impact, but also to have therapeutic value and is increasingly used to guide adjuvant treatment decisions. Advanced and recurrent disease management has also been revolutionised by increasing the use of debulking surgery and targeted treatments, particularly immunotherapy. This review summarises the recent advances in the prevention, diagnosis and treatment of endometrial cancer and seeks to identify areas for future research.

show abstract

Section: Advances In Early Diagnosismentioning

confidence: 99%

Section: Advances In Early Diagnosismentioning

confidence: 99%

Recent Advances in Endometrial Cancer Prevention, Early Diagnosis and Treatment

Baker-Rand,

Kitson

2024

Cancers

View full text Add to dashboard Cite

show abstract

“…Alternate diagnostic tests may be warranted to overcome the inconsistency of TVS. Recently, the use of DNA methylation testing for EC detection has been explored in various studies [58,59]. A recently published prospective cohort study in the UK compared the performance of a DNA-methylation-based test, the WID-qEC™ test, with ultrasonography for EC detection [59].…”

Section: Disparities In Endometrial Cancer Diagnosismentioning

confidence: 99%

“…Recently, the use of DNA methylation testing for EC detection has been explored in various studies [58,59]. A recently published prospective cohort study in the UK compared the performance of a DNA-methylation-based test, the WID-qEC™ test, with ultrasonography for EC detection [59]. The WID-qEC™ test uses real-time polymerase chain reaction to detect methylation in two genes, ZSCAN12 and GYPC, which are known to be associated with EC [59].…”

Section: Disparities In Endometrial Cancer Diagnosismentioning

confidence: 99%

“…A recently published prospective cohort study in the UK compared the performance of a DNA-methylation-based test, the WID-qEC™ test, with ultrasonography for EC detection [59]. The WID-qEC™ test uses real-time polymerase chain reaction to detect methylation in two genes, ZSCAN12 and GYPC, which are known to be associated with EC [59]. Conveniently, this test utilises non-invasive cervicovaginal swabs.…”

Section: Disparities In Endometrial Cancer Diagnosismentioning

confidence: 99%

See 1 more Smart Citation

Racioethnic Disparities in Endometrial Cancer Outcomes

Illah,

Adeeko,

Olaitan

et al. 2024

Diagnostics

View full text Add to dashboard Cite

Black women are twice as likely to die from endometrial cancer (EC) compared with white women. This represents one of the worst racioethnic disparities amongst all cancers globally. Compared with white women, black women are more likely to be diagnosed with advanced EC, have more barriers to accessing care and experience increased delays in obtaining an EC diagnosis and commencing treatment. Histological and molecular differences place black women at higher risk of being diagnosed with more aggressive EC subtypes that carry less favourable outcomes. Furthermore, EC diagnostic pathways are less reliable in black women, and black women are less likely to receive evidence-based treatment for EC. This racioethnic disparity in EC outcomes exists both in the UK and US, despite differences in healthcare systems. This review methodically describes the key factors along the patient journey that contribute to the disparity in black women and proposes multifaceted approaches to lessen these gaps.

show abstract

High performance of the DNA methylation‐based WID‐qEC test for detecting uterine cancers independent of sampling modalities

Illah,

Scott,

Redl

et al. 2024

Intl Journal of Cancer

Self Cite

View full text Add to dashboard Cite

Endometrial cancer (EC) is the most prevalent gynaecological cancer in high‐income countries and its incidence is continuing to rise sharply. Simple and objective tools to reliably detect women with EC are urgently needed. We recently developed and validated the DNA methylation (DNAme)‐based women's cancer risk identification—quantitative polymerase chain reaction test for endometrial cancer (WID‐qEC) test that could address this need. Here, we demonstrate that the stability of the WID‐qEC test remains consistent regardless of: (i) the cervicovaginal collection device and sample media used (Cervex brush and PreservCyt or FLOQSwab and eNAT), (ii) the collector of the specimen (gynaecologist‐ or patient‐based), and (iii) the precise sampling site (cervical, cervicovaginal and vaginal). Furthermore, we demonstrate sample stability in eNAT medium for 7 days at room temperature, greatly facilitating the implementation of the test into diagnostic laboratory workflows. When applying FLOQSwabs (Copan) in combination with the eNAT (Copan) sample collection media, the sensitivity and specificity of the WID‐qEC test to detect uterine (i.e., endometrial and cervical) cancers in gynaecologist‐taken samples was 92.9% (95% confidence interval [CI] = 75.0%–98.8%) and 98.6% (95% CI = 91.7%–99.9%), respectively, whilst the sensitivity and specificity in patient collected self‐samples was 75.0% (95% CI = 47.4%–91.7%) and 100.0% (95% CI = 93.9%–100.0%), respectively. Taken together these data confirm the robustness and clinical potential of the WID‐qEC test.

show abstract

Performance of the WID-qEC test versus sonography to detect uterine cancers in women with abnormal uterine bleeding (EPI-SURE): a prospective, consecutive observational cohort study in the UK

Cited by 5 publications

References 33 publications

Recent Advances in Endometrial Cancer Prevention, Early Diagnosis and Treatment

Recent Advances in Endometrial Cancer Prevention, Early Diagnosis and Treatment

Racioethnic Disparities in Endometrial Cancer Outcomes

High performance of the DNA methylation‐based WID‐qEC test for detecting uterine cancers independent of sampling modalities

Contact Info

Product

Resources

About